Tabula Rasa Healthcare (TRHC) Downgraded by BidaskClub to “Buy”

BidaskClub lowered shares of Tabula Rasa Healthcare (NASDAQ:TRHC) from a strong-buy rating to a buy rating in a research note issued to investors on Wednesday.

Several other brokerages have also commented on TRHC. Chardan Capital upped their price target on Tabula Rasa Healthcare from $19.50 to $21.00 and gave the stock a buy rating in a research note on Tuesday, August 8th. Robert W. Baird upped their price target on Tabula Rasa Healthcare from $17.00 to $18.00 and gave the stock an outperform rating in a research note on Tuesday, August 8th. Piper Jaffray Companies restated an overweight rating and set a $20.00 price target (up from $19.00) on shares of Tabula Rasa Healthcare in a research note on Wednesday, August 9th. UBS upped their price target on Tabula Rasa Healthcare from $18.00 to $25.00 and gave the stock a buy rating in a research note on Wednesday, August 30th. Finally, Wells Fargo & Company lowered Tabula Rasa Healthcare from an outperform rating to a market perform rating and upped their price target for the stock from $17.00 to $21.00 in a research note on Thursday, September 7th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has an average rating of Buy and an average price target of $28.25.

Tabula Rasa Healthcare (TRHC) traded down $1.49 during midday trading on Wednesday, reaching $27.51. The company had a trading volume of 1,969,300 shares, compared to its average volume of 102,888. Tabula Rasa Healthcare has a 1 year low of $11.42 and a 1 year high of $36.80. The company has a current ratio of 0.73, a quick ratio of 0.66 and a debt-to-equity ratio of 0.47.

Tabula Rasa Healthcare (NASDAQ:TRHC) last released its earnings results on Monday, November 6th. The company reported $0.08 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.02. Tabula Rasa Healthcare had a negative return on equity of 5.58% and a negative net margin of 2.27%. The firm had revenue of $33.27 million for the quarter, compared to the consensus estimate of $31.76 million. During the same period in the prior year, the business posted $0.06 earnings per share. The firm’s revenue for the quarter was up 37.6% compared to the same quarter last year. equities analysts anticipate that Tabula Rasa Healthcare will post 0.05 EPS for the current year.

In other news, insider Orsula V. Knowlton sold 8,000 shares of the stock in a transaction dated Wednesday, October 18th. The stock was sold at an average price of $26.68, for a total value of $213,440.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 45.80% of the company’s stock.

Several hedge funds have recently bought and sold shares of TRHC. TIAA CREF Investment Management LLC grew its stake in shares of Tabula Rasa Healthcare by 108.5% in the first quarter. TIAA CREF Investment Management LLC now owns 8,131 shares of the company’s stock valued at $110,000 after buying an additional 4,232 shares in the last quarter. New York State Common Retirement Fund boosted its holdings in Tabula Rasa Healthcare by 257.0% in the second quarter. New York State Common Retirement Fund now owns 10,000 shares of the company’s stock valued at $151,000 after purchasing an additional 7,199 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in Tabula Rasa Healthcare in the first quarter valued at about $178,000. Cadence Capital Management LLC purchased a new position in Tabula Rasa Healthcare in the second quarter valued at about $210,000. Finally, Financial Consulate Inc. purchased a new position in Tabula Rasa Healthcare in the third quarter valued at about $222,000. Institutional investors and hedge funds own 31.85% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Tabula Rasa Healthcare (TRHC) Downgraded by BidaskClub to “Buy”” was first reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this news story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The correct version of this news story can be accessed at https://www.chaffeybreeze.com/2017/12/07/tabula-rasa-healthcare-trhc-downgraded-by-bidaskclub-to-buy.html.

Tabula Rasa Healthcare Company Profile

Tabula Rasa HealthCare, Inc (Tabula Rasa), formerly CareKinesis, Inc, is a provider of patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations and manage risk. The Company delivers its solutions through a suite of technology-enabled products and services for medication risk management, which includes bundled prescription fulfillment and adherence packaging services for client populations with complex prescription needs.

Analyst Recommendations for Tabula Rasa Healthcare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa Healthcare Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa Healthcare Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply